Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo.

Wang Q, Li T, Wu Z, Wu Q, Ke X, Luo D, Wang H.

PLoS One. 2013 Aug 12;8(8):e70544. doi: 10.1371/journal.pone.0070544. eCollection 2013.

2.

Profile of conbercept in the treatment of neovascular age-related macular degeneration.

Lu X, Sun X.

Drug Des Devel Ther. 2015 Apr 22;9:2311-20. doi: 10.2147/DDDT.S67536. eCollection 2015. Review.

3.

Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model.

Bhuvaneswari R, Yuen GY, Chee SK, Olivo M.

Lasers Surg Med. 2011 Sep;43(7):651-62. doi: 10.1002/lsm.21109.

PMID:
22057493
4.

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.

Ferrara N, Hillan KJ, Novotny W.

Biochem Biophys Res Commun. 2005 Jul 29;333(2):328-35. Review.

PMID:
15961063
5.

Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects.

Yu DC, Lee JS, Yoo JY, Shin H, Deng H, Wei Y, Yun CO.

Mol Ther. 2012 May;20(5):938-47. doi: 10.1038/mt.2011.285. Epub 2012 Jan 24.

6.

FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.

Gao W, Jin K, Lan H, Han N, Cao F, Teng L.

Hepatogastroenterology. 2012 Nov-Dec;59(120):2543-7.

PMID:
22534543
7.

A fusion protein with the receptor-binding domain of vascular endothelial growth factor-A (VEGF-A) is an antagonist of angiogenesis in cancer treatment: Simultaneous blocking of VEGF receptor-1 and 2.

Tseng FJ, Chen YC, Lin YL, Tsai NM, Lee RP, Chung YS, Chen CH, Liu YK, Huang YS, Hwang CH, Lai YK, Liao KW.

Cancer Biol Ther. 2010 Nov 1;10(9):865-73. doi: 10.4161/cbt.10.9.13230. Epub 2010 Nov 1.

PMID:
20818186
8.
10.

The anti-angiogenic isoforms of VEGF in health and disease.

Qiu Y, Hoareau-Aveilla C, Oltean S, Harper SJ, Bates DO.

Biochem Soc Trans. 2009 Dec;37(Pt 6):1207-13. doi: 10.1042/BST0371207.

11.

Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.

Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD, Sebti SM.

Cancer Res. 2004 May 15;64(10):3586-92.

12.

VEGF as a therapeutic target in cancer.

Ferrara N.

Oncology. 2005;69 Suppl 3:11-6. Epub 2005 Nov 21. Review.

PMID:
16301831
13.

The VEGF signaling pathway in cancer: the road ahead.

Stacker SA, Achen MG.

Chin J Cancer. 2013 Jun;32(6):297-302. doi: 10.5732/cjc.012.10319. Epub 2013 Feb 19.

14.
15.

A dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo.

Mabry R, Gilbertson DG, Frank A, Vu T, Ardourel D, Ostrander C, Stevens B, Julien S, Franke S, Meengs B, Brody J, Presnell S, Hamacher NB, Lantry M, Wolf A, Bukowski T, Rosler R, Yen C, Anderson-Haley M, Brasel K, Pan Q, Franklin H, Thompson P, Dodds M, Underwood S, Peterson S, Sivakumar PV, Snavely M.

MAbs. 2010 Jan-Feb;2(1):20-34. Epub 2010 Jan 2.

16.

Observation of total VEGF level in hyperglycemic mouse eyes after intravitreal injection of the novel anti-VEGF drug conbercept.

Du L, Peng H, Wu Q, Zhu M, Luo D, Ke X, Yang P, Lei B.

Mol Vis. 2015 Feb 20;21:185-93. eCollection 2015.

17.

Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A.

Yang J, Wang X, Fuh G, Yu L, Wakshull E, Khosraviani M, Day ES, Demeule B, Liu J, Shire SJ, Ferrara N, Yadav S.

Mol Pharm. 2014 Oct 6;11(10):3421-30. doi: 10.1021/mp500160v. Epub 2014 Sep 16.

PMID:
25162961
18.

Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.

Shinkaruk S, Bayle M, Laïn G, Déléris G.

Curr Med Chem Anticancer Agents. 2003 Mar;3(2):95-117. Review.

PMID:
12678905
19.

CAPE suppresses VEGFR-2 activation, and tumor neovascularization and growth.

Chung TW, Kim SJ, Choi HJ, Kwak CH, Song KH, Suh SJ, Kim KJ, Ha KT, Park YG, Chang YC, Chang HW, Lee YC, Kim CH.

J Mol Med (Berl). 2013 Feb;91(2):271-82. doi: 10.1007/s00109-012-0952-6. Epub 2012 Aug 31.

PMID:
22935775
20.

Therapeutic anti-VEGF antibodies.

Lien S, Lowman HB.

Handb Exp Pharmacol. 2008;(181):131-50. Review.

PMID:
18071944
Items per page

Supplemental Content

Write to the Help Desk